PMID- 23981744
OWN - NLM
STAT- MEDLINE
DCOM- 20140317
LR  - 20220408
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 16
IP  - 3
DP  - 2013 Jun
TI  - HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
PG  - 254-7
LID - 10.1111/1756-185X.12050 [doi]
AB  - Gout is a common condition which is mainly treated with the hypo-uricemic agent, 
      allopurinol. Although allopurinol is generally a well-tolerated drug, there is a 
      small risk of developing potentially fatal complications, such as allopurinol 
      hypersensitivity syndrome. Recent advances in pharmacogenomics have made possible 
      the identification of genes which confer susceptibility to specific drugs. A 
      recent multi-national case-control study has reported allopurinol as the most 
      common drug associated with Stevens-Johnson syndrome and toxic epidermal 
      necrolysis. Several studies have established a strong association between the 
      human leukocyte antigen (HLA)-B*5801 gene and development of Stevens-Johnson 
      syndrome and toxic epidermal necrolysis. The allele frequency of HLA-B*5801 is 
      highest in the South East Asian population.Since other hypo-uricemic agents are 
      available, patients may wish to have HLA-B*5801 testing before being started on 
      allopurinol. As the test for HLA-B*5801 is expensive, time-consuming and only 
      available in selected laboratories, there is a need to evaluate the utility and 
      cost-effectiveness of this test in our region.
CI  - (c) 2013 The Author International Journal of Rheumatic Diseases (c) 2013 Asia Pacific 
      League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.
FAU - Yeo, Siaw Ing
AU  - Yeo SI
AD  - Division of Rheumatology and Clinical Immunology, LKS Faculty of Medicine, The 
      University of Hong Kong, Hong Kong, China. ingyeo@hotmail.com
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130426
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Gout Suppressants)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*58:01 antigen)
RN  - 63CZ7GJN5I (Allopurinol)
SB  - IM
MH  - Allopurinol/*adverse effects
MH  - Asia
MH  - Australasia
MH  - Cost-Benefit Analysis
MH  - Drug Hypersensitivity Syndrome/*genetics/immunology/prevention & control
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing/*economics
MH  - Gout/*drug therapy
MH  - Gout Suppressants/*adverse effects
MH  - HLA-B Antigens/*genetics
MH  - *Health Care Costs
MH  - Humans
MH  - Patient Selection
MH  - Pharmacogenetics/*economics
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - Stevens-Johnson Syndrome/*genetics/immunology/prevention & control
OTO - NOTNLM
OT  - HLA-B*5801
OT  - Stevens-Johnson syndrome
OT  - allopurinol hypersensitivity syndrome
OT  - severe cutaneous adverse reactions
OT  - toxic epidermal necrolysis
EDAT- 2013/08/29 06:00
MHDA- 2014/03/19 06:00
CRDT- 2013/08/29 06:00
PHST- 2013/08/29 06:00 [entrez]
PHST- 2013/08/29 06:00 [pubmed]
PHST- 2014/03/19 06:00 [medline]
AID - 10.1111/1756-185X.12050 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2013 Jun;16(3):254-7. doi: 10.1111/1756-185X.12050. Epub 2013 
      Apr 26.